抗生素在肿瘤发生发展及免疫治疗中的作用

doi:10.3760/cma.j.cn371439-20200423-00009

国际肿瘤学杂志 ›› 2021, Vol. 48 ›› Issue (1): 48-51.doi: 10.3760/cma.j.cn371439-20200423-00009

抗生素在肿瘤发生发展及免疫治疗中的作用

杨梦雪, 袁满, 童建东, 严雪冰()

扬州大学附属医院肿瘤科 225000

收稿日期:2020-04-23 修回日期:2020-08-27 出版日期:2021-01-08 发布日期:2021-01-21
通讯作者: 严雪冰 E-mail:yyxxbb8904@163.com
基金资助:
国家自然科学基金(81902422)

Role of antibiotics in tumor development and immunotherapy

Yang Mengxue, Yuan Man, Tong Jiandong, Yan Xuebing()

Department of Oncology, Affiliated Hospital of Yangzhou University, Yangzhou 225000, China

Received:2020-04-23 Revised:2020-08-27 Online:2021-01-08 Published:2021-01-21
Contact: Yan Xuebing E-mail:yyxxbb8904@163.com
Supported by:
National Natural Science Foundation of China(81902422)

摘要/Abstract

摘要：

近年来,以免疫检查点抑制剂(ICI)为代表性药物的肿瘤免疫治疗成为晚期恶性肿瘤重要的治疗方法。临床前研究发现,肠道微生物群紊乱会降低应用ICI患者的临床获益。最新的数据表明,抗生素可能通过改变肠道微生物群的丰度及组成进一步影响肿瘤的发生发展及免疫治疗疗效。总结抗生素在晚期恶性肿瘤免疫治疗中的作用,可为优化晚期肿瘤患者治疗策略提供新思路。

关键词: 抗菌药, 免疫疗法, 微生物群, 预后

Abstract:

In recent years, immunotherapy with immune checkpoint inhibitor (ICI) as the representative drug has become an important treatment method for advanced malignant tumors. Preclinical studies have found that disorders of the gut microbiota can reduce the clinical benefit of patients treated with ICI. The latest data indicate that antibiotics may further affect the occurrence and development of tumors and the efficacy of immunotherapy by changing the abundance and composition of intestinal microbiota. To sum up the role of anti-biotics in the immunotherapy of advanced malignant tumor may provide a new idea for the optimization of treatment strategies for patients with advanced cancer.

Key words: Anti-bacterial agents, Immunotherapy, Microbiota, Prognosis

杨梦雪, 袁满, 童建东, 严雪冰. 抗生素在肿瘤发生发展及免疫治疗中的作用[J]. 国际肿瘤学杂志, 2021, 48(1): 48-51.

Yang Mengxue, Yuan Man, Tong Jiandong, Yan Xuebing. Role of antibiotics in tumor development and immunotherapy[J]. Journal of International Oncology, 2021, 48(1): 48-51.

参考文献 26

[1]	Hartmann FJ, Babdor J, Gherardini PF, et al. Comprehensive immune monitoring of clinical trials to advance human immunotherapy[J]. Cell Rep, 2019,28(3): 819-831.e4. DOI: 10.1016/j.celrep.2019.06.049.
[2]	Nie P, Li Z, Wang Y, et al. Gut microbiome interventions in human health and diseases[J]. Med Res Rev, 2019,39(6):2286-2313. DOI: 10.1002/med.21584. doi: 10.1002/med.21584 pmid: 30994937
[3]	Wei MY, Shi S, Liang C, et al. The microbiota and microbiome in pancreatic cancer: more influential than expected[J]. Mol Cancer, 2019,18(1):97. DOI: 10.1186/s12943-019-1008-0. pmid: 31109338
[4]	Baba Y, Iwatsuki M, Yoshida N, et al. Review of the gut microbiome and esophageal cancer: pathogenesis and potential clinical implications[J]. Ann Gastroenterol Surg, 2017,1(2):99-104. DOI: 10.1002/ags3.12014. pmid: 29863142
[5]	Bullman S, Pedamallu CS, Sicinska E, et al. Analysis of fusobacte-rium persistence and antibiotic response in colorectal cancer[J]. Science, 2017,358(6369):1443-1448. DOI: 10.1126/science.aal5240. pmid: 29170280
[6]	Wirbel J, Pyl PT, Kartal E, et al. Meta-analysis of fecal metagenomes reveals global microbial signatures that are specific for colorectal cancer[J]. Nat Med, 2019,25(4):679-689. DOI: 10.1038/s41591-019-0406-6. doi: 10.1038/s41591-019-0406-6 pmid: 30936547
[7]	Alexander JL, Wilson ID, Teare J, et al. Gut microbiota modulation of chemotherapy efficacy and toxicity[J]. Nat Rev Gastroenterol Hepatol, 2017,14(6):356-365. DOI: 10.1038/nrgastro.2017.20. doi: 10.1038/nrgastro.2017.20 pmid: 28270698
[8]	Wang Y, Wiesnoski DH, Helmink BA, et al. Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis[J]. Nat Med, 2018,24(12):1804-1808. DOI: 10.1038/s41591-018-0238-9. doi: 10.1038/s41591-018-0238-9 pmid: 30420754
[9]	Rosa CP, Brancaglion GA, Miyauchi-Tavares TM, et al. Antibiotic-induced dysbiosis effects on the murine gastrointestinal tract and their systemic repercussions[J]. Life Sci, 2018,207:480-491. DOI: 10.1016/j.lfs.2018.06.030. doi: 10.1016/j.lfs.2018.06.030 pmid: 30056862
[10]	Russell B, Garmo H, Beckmann K, et al. A case-control study of lower urinary-tract infections, associated antibiotics and the risk of developing prostate cancer using PCBaSe 3.0[J]. PLoS One, 2018,13(4):e0195690. DOI: 10.1371/journal.pone.0195690. doi: 10.1371/journal.pone.0195690 pmid: 29649268
[11]	Zhang J, Haines C, Watson AJM, et al. Oral antibiotic use and risk of colorectal cancer in the United Kingdom, 1989-2012: a matched case-control study[J]. Gut, 2019,68(11):1971-1978. DOI: 10.1136/gutjnl-2019-318593. doi: 10.1136/gutjnl-2019-318593 pmid: 31427405
[12]	Petrelli F, Ghidini M, Ghidini A, et al. Use of antibiotics and risk of cancer: a systematic review and meta-analysis of observational studies[J]. Cancers (Basel), 2019,11(8):1174. DOI: 10.3390/cancers11081174.
[13]	Sethi V, Kurtom S, Tarique M, et al. Gut microbiota promotes tumor growth in mice by modulating immune response[J]. Gastroenterology, 2018,155(1):33-37.e6. DOI: 10.1053/j.gastro.2018.04.001. pmid: 29630898
[14]	Yan C, Tu XX, Wu W, et al. Antibiotics and immunotherapy in gastrointestinal tumors: friend or foe?[J]. World J Clin Cases, 2019,7(11):1253-1261. DOI: 10.12998/wjcc.v7.i11.1253. doi: 10.12998/wjcc.v7.i11.1253 pmid: 31236389
[15]	Schoenfeld AJ, Hellmann MD. Acquired resistance to immune checkpoint inhibitors[J]. Cancer Cell, 2020,37(4):443-455. DOI: 10.1016/j.ccell.2020.03.017. doi: 10.1016/j.ccell.2020.03.017 pmid: 32289269
[16]	Hermel DJ, Sigal D. The emerging role of checkpoint inhibition in microsatellite stable colorectal cancer[J]. J Pers Med, 2019,9(1):5. DOI: 10.3390/jpm9010005.
[17]	Eng C, Kim TW, Bendell J, et al. Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial[J]. Lancet Oncol, 2019,20(6):849-861. DOI: 10.1016/S1470-2045(19)30027-0. doi: 10.1016/S1470-2045(19)30027-0 pmid: 31003911
[18]	Aguiar PN Jr, De Mello RA, Hall P, et al. PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: updated survival data[J]. Immunotherapy, 2017,9(6):499-506. DOI: 10.2217/imt-2016-0150. doi: 10.2217/imt-2016-0150 pmid: 28472902
[19]	Derosa L, Hellmann MD, Spaziano M, et al. Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer[J]. Ann Oncol, 2018,29(6):1437-1444. DOI: 10.1093/annonc/mdy103. pmid: 29617710
[20]	Pinato DJ, Howlett S, Ottaviani D, et al. Association of prior anti-biotic treatment with survival and response to immune checkpoint inhibitor therapy in patients with cancer[J]. JAMA Oncol, 2019,5(12):1774-1778. DOI: 10.1001/jamaoncol.2019.2785. doi: 10.1001/jamaoncol.2019.2785 pmid: 31513236
[21]	Routy B, Le Chatelier E, Derosa L, et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors[J]. Science, 2018,359(6371):91-97. DOI: 10.1126/science.aan3706. pmid: 29097494
[22]	Kaderbhai C, Richard C, Fumet JD, et al. Antibiotic use does not appear to influence response to nivolumab[J]. Anticancer Res, 2017,37(6):3195-3200. DOI: 10.21873/anticanres.11680. doi: 10.21873/anticanres.11680 pmid: 28551664
[23]	Tinsley N, Zhou C, Tan G, et al. Cumulative antibiotic use significantly decreases efficacy of checkpoint inhibitors in patients with advanced cancer[J]. Oncologist, 2020,25(1):55-63. DOI: 10.1634/theoncologist.2019-0160. doi: 10.1634/theoncologist.2019-0160 pmid: 31292268
[24]	Ahmed J, Kumar A, Parikh K, et al. Use of broad-spectrum anti-biotics impacts outcome in patients treated with immune checkpoint inhibitors[J]. Oncoimmunology, 2018,7(11):e1507670. DOI: 10.1080/2162402X.2018.1507670. doi: 10.1080/2162402X.2018.1507670 pmid: 30377571
[25]	Huang XZ, Gao P, Song YX, et al. Antibiotic use and the efficacy of immune checkpoint inhibitors in cancer patients: a pooled analysis of 2740 cancer patients[J]. Oncoimmunology, 2019,8(12):e1665973. DOI: 10.1080/2162402X.2019.1665973. doi: 10.1080/2162402X.2019.1665973 pmid: 31741763
[26]	Suez J, Zmora N, Zilberman-Schapira G, et al. Post-antibiotic gut mucosal microbiome reconstitution is impaired by probiotics and improved by autologous FMT[J]. Cell, 2018,174(6):1406-1423.e16. DOI: 10.1016/j.cell.2018.08.047. pmid: 30193113

抗生素在肿瘤发生发展及免疫治疗中的作用

Role of antibiotics in tumor development and immunotherapy

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 26

相关文章 15

编辑推荐

Metrics

本文评价

[1]	钱晓涛, 石子宜, 胡格, 吴晓维. Ⅲ~ⅣA期食管鳞状细胞癌放化疗后行巩固化疗的疗效：一项真实世界临床研究[J]. 国际肿瘤学杂志, 2024, 51(6): 326-331.
[2]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊. 局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[3]	高凡, 王萍, 杜超, 褚衍六. 肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[4]	范志鹏, 余静, 胡静, 廖正凯, 徐禹, 欧阳雯, 谢丛华. 炎症标志物的变化趋势对一线接受免疫联合化疗的晚期非小细胞肺癌患者预后的预测价值[J]. 国际肿瘤学杂志, 2024, 51(5): 257-266.
[5]	杨琳, 路宁, 温华, 张明鑫, 朱琳. 炎症负荷指数与胃癌临床关系研究[J]. 国际肿瘤学杂志, 2024, 51(5): 274-279.
[6]	张文馨, 夏泠, 彭晋, 周福祥. 甲胎蛋白升高型胃肝样腺癌1例并文献复习[J]. 国际肿瘤学杂志, 2024, 51(5): 312-315.
[7]	刘萍萍, 何学芳, 张翼, 杨旭, 张珊珊, 季一飞. 原发性脑胶质瘤患者术后复发危险因素及预测模型构建[J]. 国际肿瘤学杂志, 2024, 51(4): 193-197.
[8]	万芳, 杨钢, 李睿, 万启晶. 食管癌患者血清miR-497、miR-383水平及临床意义[J]. 国际肿瘤学杂志, 2024, 51(4): 204-209.
[9]	杨毫, 施贵冬, 张程城, 张跃, 张力文, 付茂勇. 信迪利单抗与替雷利珠单抗在进展期食管鳞状细胞癌新辅助治疗中的疗效及安全性对比[J]. 国际肿瘤学杂志, 2024, 51(4): 210-216.
[10]	姚益新, 沈煜霖. 血清SOCS3、TXNIP水平对肝细胞癌TACE治疗预后的预测价值[J]. 国际肿瘤学杂志, 2024, 51(4): 217-222.
[11]	萨蔷, 徐航程, 王佳玉. 乳腺癌免疫治疗研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 227-234.
[12]	张栋岩, 王品, 魏秋亚, 邓成伍, 魏相相, 高远飞, 王琛. 索凡替尼靶向联合卡培他滨和奥沙利铂治疗肝内胆管癌术后患者1例及文献复习[J]. 国际肿瘤学杂志, 2024, 51(4): 249-253.
[13]	孙维蔚, 姚学敏, 王鹏健, 王静, 贾敬好. 基于血液学指标探讨免疫治疗晚期非小细胞肺癌预后因素及列线图构建[J]. 国际肿瘤学杂志, 2024, 51(3): 143-150.
[14]	刘玉兰, 井海燕, 孙静, 宋伟, 沙丹. 胃癌免疫治疗疗效预测及预后标志物的研究进展[J]. 国际肿瘤学杂志, 2024, 51(3): 175-180.
[15]	彭琴, 蔡玉婷, 王伟. KPNA2在肝癌中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(3): 181-185.